Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marcella Mandruzzato"'
Autor:
Maria A. Pantaleo, Marcella Mandruzzato, Valentina Indio, Milena Urbini, Margherita Nannini, Lidia Gatto, Angela Schipani, Michelangelo Fiorentino, Tania Franceschini, Valentina Ambrosini, Valerio Di Scioscio, Maristella Saponara, Manuela Ianni, Sergio Concetti, Annalisa Altimari, Andrea Ardizzoni, Annalisa Astolfi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Somatic malignant transformation in a germ cell tumor (GCT) is the development of non-germ malignancies; much of available literature refers to teratoma with malignant transformation (TMT). There are various transformation histologies such as sarcoma
Externí odkaz:
https://doaj.org/article/590682167ce34a688a1ae5658f6d9322
Autor:
Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, Danilo Rocco, Giulia Pasello, Fabiana Letizia Cecere, Antonio Chella, Giada Grilli, Marcella Mandruzzato, Michele Tognetto, Marina Chiara Garassino, Marianna Macerelli, Silvia Novello, Fausto Roila, Ida Colantonio, Francesco Grossi, Michelangelo Fiorentino, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histo
Externí odkaz:
https://doaj.org/article/6b7e2a7ed1fa49fe8fd2a640704b2cb2
Autor:
Michelangelo Fiorentino, Fausto Roila, Fabiana Letizia Cecere, Giulia Pasello, Andrea Ardizzoni, Silvia Novello, Francesco Gelsomino, Giada Grilli, Marianna Macerelli, Giuseppe Lamberti, Michele Tognetto, I. Colantonio, Marina Chiara Garassino, Antonio Chella, Marcello Tiseo, Marcella Mandruzzato, Francesco Grossi, Danilo Rocco
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background: Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73949cdabd764f065b3dc4650b94c660
http://hdl.handle.net/11577/3367851
http://hdl.handle.net/11577/3367851
